Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome by Acharya, S. K. et al.
Fulminant Hepatitis in a Tropical Population: Clinical
Course, Cause, and Early Predictors of Outcome
S. K. ACHARYA,1 S. DASARATHY,1 TALI L. KUMER,1 S. SUSHMA,1 K. S. UMA PRASANNA,1 A. TANDON,1
V. SREENIVAS,2 S. NIJHAWAN,1 S. K. PANDA,3 S. K. NANDA,3 M. IRSHAD,1 Y. K. JOSHI,1 S. DUTTAGUPTA,3
R. K. TANDON,1 AND B. N. TANDON1
rum bilirubin, and prothrombin time prolongation overThe profiles of patients with fulminant hepatic failure
controls at admission were related to survival (P  .01).(FHF) from developing countries have not been reported
The rapidity of onset of encephalopathy and cause ofearlier. The current study was conducted prospectively,
FHF did not influence the outcome. Cox’s proportionalat a single tertiary care center in India, to document the
hazard regression showed age ¢40 years, presence ofdemographic and clinical characteristics, natural
cerebral edema, serum bilirubin ¢15 mg/dL, and pro-course, and causative profile of patients with FHF as
thrombin time prolongation of 25 seconds or more overwell as to define simple prognostic markers in these pa-
controls were independent predictors of outcome.tients. Four hundred twenty-three consecutive patients
Ninety-three percent of the patients with three or morewith FHF admitted from January 1987 to June 1993 were
of the above prognostic markers died. The sensitivity,included in the study. Each patient’s serum was tested
specificity, positive predictive value, and the negativefor various hepatotropic viruses. Univariate Cox’s re-
predictive value of the presence of three or more of thesegression for 28 variables, multivariate Cox’s propor-
prognostic factors for mortality was 93%, 80%, 86%, andtional hazard regression, stepwise logistic regression,
89.5%, respectively, with a diagnostic accuracy of 87.3%.and Kaplan-Meier survival analysis were done to iden-
We conclude that most of our patients with FHF mighttify independent predictors of outcome at admission. All
have been caused by hepatotropic viral infection, andpatients presented with encephalopathy within 4 weeks
non-A, non-B virus(es) seems to be the dominant hepato-of onset of symptoms. Hepatotropic viruses were the
tropic viral infection among these patients. They pre-likely cause in most of these patients. Hepatitis A (HAV),
sented with encephalopathy within 4 weeks of the onsethepatitis B (HBV), hepatitis D (HDV) viruses, and antitu-
of symptoms. Pregnancy, cause, and rapidity of onset ofbercular drugs could be implicated as the cause of FHF
encephalopathy did not influence survival. The prog-in 1.7% (n  7), 28% (n  117), 3.8% (n  16), and 4.5% (n
nostic model developed in the current study is simple 19) patients, respectively. In the remaining 62% (n
and can be performed at admission. (HEPATOLOGY 264) of patients the serological evidence of HAV, HBV,
1996;23:1448-1455.)or HDV infection was lacking, and none of them had
ingested hepatotoxins. FHF was presumed to be caused
by non-A, non-B virus(es) infection. Sera of 50 patients
Most reports on fulminant hepatic failure (FHF)from the latter group were tested for hepatitis E virus
(HEV) RNA and HCV RNA. In 31 (62%), HEV could be have been predominantly from the West,1-9 and particu-
implicated as the causative agent, and isolated HCV larly from three countries: the United Kingdom,1,2 Ja-
RNA could be detected in 7 (19%). Two hundred eighty- pan,3,4 and France.5 Based on these geographically lim-
eight (66%) patients died. Approximately 75% of those ited observations, a new classification of this disease
who died did so within 72 hours of hospitalisation. One entity into hyperacute, acute, and subacute liver fail-
quarter of the female patients with FHF were pregnant. ure has been suggested.2 These authors also suggestedMortality among pregnant females, nonpregnant fe- the adoption of this classification universally for a uni-males, and male patients with FHF was similar (P  .1).
form terminology. The latter study has not been ableUnivariate analysis showed that age, size of the liver
to consider the disease characteristics in the tropicalassessed by percussion, grade of coma, presence of clini-
population, presumably because of the lack of pub-cal features of cerebral edema, presence of infection, se-
lished data from the tropics.
The cause and rapidity of the onset of hepatic enceph-
Abbreviations: FHF, fulminant hepatic failure; Ig, immunoglobulin; HAV, alopathy in patients with FHF have been reported as
hepatitis A virus; HDV, hepatitis D virus; HBV, hepatitis B virus; HEV, hepati- important prognostic predictors.1-3 However, the cause
tis E virus; HCV, hepatitis C virus. of FHF may have regional differences, and the rapidity
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Grade IV: Unconscious, no response to external stimulisound, blood ammonia levels, galactose elimination ca-
except decerebrate posturing to painful stimulipacity, and bile acid conjugation, have been suggested
Cerebral Edema.23,24 Cerebral edema was defined by theto distinguish survivors and nonsurvivors among pa-
presence of spontaneous decerebrate posturing, hypertensiontients with FHF.1-3,6-8,10-15 The prognostic criteria for
(supine blood pressure 150/90 mm Hg), bradycardia (pulseFHF developed at King’s college, London,1 and at Cli- rate 10 beats/min from the expected pulse rate for givenchy, France,5 when reevaluated at another center, were body temperature), pupillary changes, and presence of neuro-
found to have a lower specificity and sensitivity than genic hyperventilation. Neurogenic hyperventilation was di-
reported in the original studies.16 Orthotopic liver agnosed by the presence of hyperventilation in the absence
transplantation has become an established treatment of any metabolic or respiratory cause for hyperventilation.
Presence of decerebrate posturing alone or the presence ofoption in patients with FHF17-21 and is gradually be-
any two of the four features were considered as evidence ofcoming available in developing nations. Hence, there
cerebral edema.is a need for a prognostic model in patients with FHF
Sepsis. Sepsis was diagnosed in the presence of pyrexiain these countries.
(body temperature 1017F) or hypothermia (body tempera-The current study on FHF therefore was conducted
ture 987F) and neutrophilic leucocytosis (total leucocyteprospectively in a single tertiary care center in North count 15,000/mm3 with 80% or more polymorphs) and oneIndia to identify the demographic characteristics, caus- or more of the following: positive blood culture, positive urine
ative spectrum, clinical features, natural course, and culture, radiological evidence of pneumonitis.
predictors of outcome among patients with FHF. Cause of Death. The immediate antecedent event oc-
curring within 12 hours of death, in the absence of any other
PATIENTS AND METHODS possible factor that could cause a fatal outcome, was consid-
ered as the cause of death.Patients
Coagulopathy. Prolongation of prothrombin time by more
Consecutive patients with FHF admitted to the gastroen- than 4 seconds over controls was considered as evidence of
terology ward of the All India Institute of Medical Sciences, abnormal clotting mechanism. This was determined from the
New Delhi, between January 1987 and June 1993 were in- distribution of the prothrombin time among normal subjects.
cluded in the study. Values were considered abnormal when they were beyond
Diagnosis of FHF. The diagnosis of FHF was made by the the mean { 3 SD range at our laboratory. Thromboplastin
presence of encephalopathy within 8 weeks of onset of ill- was derived from rabbit brain (Biopool Inc., CA) with an
ness.12 Diagnosis of FHF was confirmed by presence of sub- international sensitivity index value of 1.8.
massive or massive necrosis in the postmortem liver biopsy
specimen in patients who died. Consent for the postmortem Treatment Schedule
liver biopsy was obtained from the nearest relative of the
All patients were given standard supportive treatmentdeceased after explaining the purpose of the biopsy. Liver
with energetic intensive care monitoring. H2 receptor antago-biopsy in the survivors was performed whenever possible
nists for stress ulcer prophylaxis, appropriate antibiotics forafter their coagulation profile was corrected and an informed
sepsis, parenteral mannitol (20%), and ventilatory supportconsent was obtained.
for cerebral edema, fresh frozen plasma as and when re-Exclusion Criteria. Patients in whom the history was un-
quired, gut sterilization, and mantainance of fluid and elec-reliable or the diagnosis was not confirmed by a combination
trolytes were the mainstay of therapy.of typical clinical features, liver function tests, and viral
markers with or without liver biopsy were excluded.
MethodsChronic liver disease was excluded by liver biopsy. In pa-
tients in whom a liver biopsy was not possible because of a Each patient had clinical evaluation at admission and ev-
deranged coagulation profile, the diagnosis of chronic liver ery 1 to 2 hours thereafter. History of consumption of hepato-
disease was made on clinical, biochemical, and imaging crite- toxic drugs or indigenous treatment such as herbal therapy
ria. was inquired of the relatives of each patient. Liver dullness
by percussion at admission was assessed by at least two phy-Study Variables
sicians (one resident and one consultant) at admission and
subsequently twice daily.25-27 Pregnancy was diagnosed by aDuration of Prodrome. Period from onset of symptoms to
the onset of icterus history of amenorrhea, urinary human chorionic gonadotro-
phin assay, and bedside ultrasound. The trimesters of preg-Icterus-Encephalopathy Interval. Interval between detec-
tion of icterus to onset of hepatic encephalopathy nancy were calculated from the history and sonographic as-
sessment of fetal dimensions.Pre-encephalopathy Period. Duration from onset of symp-
toms to onset of encephalopathy Blood was drawn at admission and subsequently every day
for liver function tests and various hematologic and biochemi-Duration of Coma. Time from onset of encephalopathy till
complete recovery from encephalopathy or death. Complete cal assays. Sera were separated and stored at 0707C for sub-
sequent viral assays.recovery from encephalopathy was considered when the pa-
tient became conscious and was found to be oriented to time, Viral Markers. Each patient’s serum sample was screened
for hepatitis B surface antigen, immunoglobulin (Ig) M anti-place, and person.
Grade of Coma. Coma was classified into four grades22: HBc, and IgM anti-hepatitis A virus (HAV) using commercial
micro-enzyme-linked immunosorbent assay test kits (Or-Grade I: Loss of sleep rhythm, presence of drowsiness, con-
fusion, hepatic flap ganon, Teknika, Netherlands; and Abbott). Serum samples
positive for hepatitis B surface antigen or IgM anti-HBc wereGrade II: Features of grade I encephalopathy with loss of
sphincter control also tested for the presence of anti-hepatitis D virus (HDV).
Tests for both IgG and IgM anti-HDV antibody were per-Grade III: Unconscious, no response to oral commands,
but responds to painful external stimuli formed using commercial enzyme-linked immunosorbent
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TABLE 1. Demographic and Clinical Profile of Patients With FHF
Survivors Nonsurvivors Total
Number 143 (34%) 280 (66%) 423
M:F 71:72 (1:1) 129:151 (1:1.2) 200:223 (1:1.1)
Age
mean { SE* 26.5 { 0.9 31.4 { 0.8 29.5 { 0.6
range (14-65) (7-80) (7-80)
Prodrome 128 (89.5%) 246 (89%) 374 (88%)
Duration of prodrome (d)
mean { SE 4.4 { 0.6 5.2 { 0.4 4.7 { 0.5
range (0-20) (0-22) (0-22)
Duration of preencephalopathy period (d)
mean { SE 5.8 { 0.5 6.3 { 0.4 5.7 { 0.2
range (0-28) (0-28) (0-28)
Preencephalopthy period (d)†
0-7 117 (81.8%) 224 (80.0%) 341 (80.6%)
8-14 17 (11.9%) 37 (13.2%) 54 (12.8%)
15-21 6 (4.2%) 13 (4.6%) 19 (4.5%)
22-28 3 (2.1%) 6 (2.1%) 9 (2.1%)
Icterus-encephalopathy interval (d)
mean { SE 4.3 { 0.5 4.9 { 0.3 4.7 { 0.3
range (0-21) (0-21) (0-21)
Icterus-encephalopathy interval (d)‡
0-7 104 (72.7%) 201 (71.8%) 305 (72.1%)
8-14 23 (16.1%) 48 (17.1%) 71 (16.8%)
15-21 16 (11.2%) 31 (11.1%) 47 (11.1%)
22-28 Nil Nil Nil
* P  .0001; only three patients were younger than 15 years. Other parameters were similar amongst survivors and nonsurvivors (P 
.1).
† 224 of 341 (66%) patients with FHF presenting with encephalopathy within 1 week of onset of symptoms died, in comparison with 56
of 82 (68%) similar patients who had encephalopathy after 1 week of onset of symptoms (P  .1). Similar observations were made when
mortality rate was compared amongst patients presenting with encephalopathy within 2 weeks and after 2 weeks of onset of symptoms.
‡ 201 of 305 (66%) patients who presented with encephalopathy within 1 week of onset of icterus died, in comparison with 79 of 118
(67%) patients developing FHF after 1 week of onset of icterus (P  .1).
assay kits (Wellcome UK). Non-A, non-B FHF was diagnosed mer hybridization31 with internal oligoprobes and labeled
with [32P]adenosine triphosphate (New England Nuclear,when the serum was negative for all of the above markers in
the absence of a history of intake of hepatotoxins. Boston, MA). The detailed steps of the procedure have al-
ready been reported elsewhere.32Sera from 50 consecutive patients with non-A, non-B fulmi-
nant hepatitis were also tested for hepatitis B virus (HBV)
Statistical AnalysisDNA to detect cryptic HBV infection, hepatitis E virus (HEV)
RNA by reverse-transcription nested polymerase chain reac-
Among survivors and nonsurvivors, qualitative variablestion using primers from nonstructural region of ORF-1, and
were compared using the x2 test. Quantitative variables werehepatitis C virus (HCV) RNA by reverse-transcription nested
compared using the Student’s t test. Univariate Cox’s regres-polymerase chain reaction, using primers from the 5* non-
sion, multivariate Cox’s regression, and multiple stepwisetranslated region.28-30 All samples were tested in duplicate.
logistic regression were performed using the BMDP softwareThe amplified polymerase chain reaction products were con-
(University of California).33-37 This was done to identify pre-firmed either by Southern hybridization29 or by liquid oligo-
dictive variables for prognosis in patients with FHF. Kaplan-
Meier survival analysis was performed for different strata of
patients.38,39 The specificity and sensitivity for each predictor
TABLE 2. Causes of FHF identified on multivariate analysis and the combination
thereof was then assessed.Survivors Nonsurvivors Total (%)
Cause (n  143) (n  280) (n  423)
RESULTS
HAV 3 (2%) 4 (1.4%) 7 (1.7%)
HBV 39 (27%) 78 (27.8%) 117 (27.6%) During the study period, 430 patients with FHF were
HDV 5 (3.5%) 11 (3.9%) 16 (3.8%) hospitalized, which accounted for 8% of our total hospi-
Non-A, non-B 89 (62.2%) 175 (63%) 264 (62.4%)* talized patients (n  5,354) during the above period.
Antitubercular drug 7 (5%) 12 (4.3%) 19 (4.5%) Diagnosis was confirmed in 423 patients who were in-
cluded in the present study. One hundred forty-threeNOTE. The causative profile amongst survivors and nonsurvivors
(34%) patients survived, and the remaining 280 (66%)was similar (P  .1).
patients died. Most patients who died had histological* Twenty-three (8.7%) were HBV carriers (HBsAg positive but
IgM anti-HBc negative). evidence of either submassive hepatic necrosis or mas-
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TABLE 3. Dichotomous Variables Influencing Outcome athy after 4 weeks of onset of symptoms of acute hepati-
(Univariate Analysis) tis (Table 1). The mean ({SE) duration between onset
of symptoms and encephalopathy was 5.7 ({0.2) days.Survivors Nonsurvivors
Variables (n  143) (n  280) An analysis of the icterus-encephalopathy interval
showed that 376 (89%) patients in the current seriesAge*
developed encephalopathy within 2 weeks of onset of40 yr 129 208
icterus, and all patients had encephalopathy within 3¢40 yr 14 72
weeks of onset of icterus. The mean ({SE) intervalGrade of coma†
I 17 (11.9%) 26 (9.3%) between detection of icterus and encephalopathy was
II 44 (30.8%) 26 (9.3%) 4.7 ({0.3) days.
III 45 (31.5%) 87 (31.1%) There were 223 (53%) women or girls, a quarter (n
IV 37 (25.9%) 141 (50.4%)  53) of whom were pregnant. The mortality rates were
Mean grade of coma‡ 2.7 { 0.1 (0-4) 3.2 { 0.1 (0-4) similar (P .1) among pregnant women (35 of 53, 66%),
Liver size (in percussion space)* age-matched nonpregnant women (116 of 170, 68%),2 56 (39.1%) 193 (68.9%) and male patients with FHF (129 of 200, 65%). The¢2 87 (60.9%) 87 (31.1%)
mortality rate was also similar (P  .1) among preg-Mean size of liver (percussion
nant women during the first, second, and third trimes-space)† 2.8 { 0.1 (0-6) 2.0 { 0.1 (0-5)
ters.Cerebral edema at admission* 44 (30.8%) 201 (71.8%)
Infection at admission* 7 (4.9%) 38 (13.6%) Among the 280 patients with a fatal outcome, death
Serum bilirubin (mg/dL)‡ occurred in 207 (74%) within 72 hours of hospitaliza-
15 100 (69.9%) 121 (43.3%) tion, and 254 (94%) died within a week of hospitaliza-
¢15 43 (30.1%) 159 (56.7%) tion. A Kaplan-Meier survival analysis showed that the
Prothombin time prolongation mean ({ SE) survival time was 1.03 ({0.9) days, and
over controls (s)* the median survival was 4 days. All deaths except one25 115 (80.4%) 154 (55%) occurred within 1 week of onset of hepatic encephalopa-¢25 28 (19.6%) 126 (45%)
thy. Cerebral edema was the single most important
* P  .0001. cause of death among our patients (71.8%). The other
† P  .01. causes of death were sepsis (23.9%), renal failure
‡ P  .001. (2.9%), and gastrointestinal bleeding (1.4%).
Cause
The causes of FHF are shown in Table 2. HAV, HBV,sive necrosis. Liver biopsy could be done in 83 patients
who survived, within 3 weeks of recovery, and showed and HDV could be incriminated in 7 (1.7%), 117 (28%),
and 16 (3.8%) patients, respectively. Nineteen (4.5%)the presence of acute hepatitis with bridging necrosis
in all. In the remaining survivors, the diagnosis was patients negative for all of these viral markers had
consumed antituberculous drugs (which included ri-achieved by clinical and biochemical features.
fampicin and isoniazid in optimal doses) for a mean
Clinical and Demographic Profile ({SD) period of 28 ({9) days (range, 13-64 days). It
was presumed that antitubercular agents caused acuteThe demographic profile of the patients is shown in
Table 1. Most patients (n  334) were younger than 40 hepatitis in these patients. The remaining 264 (62.4%)
patients did not have any identifiable markers of acuteyears of age, and the male-to-female ratio was 1:1.1. A
prodrome of fever, anorexia, or vomiting was present HAV, HBV, and HDV infections in their sera. None
of these patients had history of consumption of anyin 374 (88%) patients. The presence or duration of pro-
drome, preencephalopathy period, icterus-encephalop- identifiable hepatotoxins, particularly herbal drugs.
Their clinical and biochemical features were suggestiveathy interval, and the duration of hepatic encephalopa-
thy among survivors and nonsurvivors were similar (P of acute viral hepatitis. These patients were considered
to have non-A, non-B viral infection. Sera from 50 con- .1) (Table 1). Encephalopathy developed within 14
days in 395 (93.4%) patients, and none had encephalop- secutive patients with non-A, non-B FHF were ana-
TABLE 4. Variables Derived From Multiple Logistic Regression
Log Improvement
Step No. Term Entered df Likelihood in x2 P
0 0250.03
1 Cerebral edema at admission 1 0217.8 64.5 .00001
2 Serum Bilirubin ¢15 mg/dL 1 0208.1 19.5 .0001
3 Prothrombin time ¢25 s over control 1 0200.7 14.7 .0001
4 Age ¢40 yr 1 0193.7 14.2 .0001
5 Grade of coma III or IV 1 0191.1 5.0 .025
6 Infection 1 0188.8 4.7 .03
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TABLE 5. Multiple Logistic Regression
Exponential Lower Upper
Term Coefficient SE Coefficient/SE Coefficient Band Band
Age ¢40 yr 1.3 0.37 3.6 3.8 1.8 7.9
Grade of coma 2 0.7 0.31 2.4 2.1 1.1 3.7
Cerebral edema 1.3 0.29 4.5 3.6 2.1 6.3
Infection 1.0 0.49 2.1 2.8 1.0 7.3
Serum Bilirubin ¢ 15 mg/dL 1.1 0.26 3.9 2.8 1.7 4.6
Prothombin time (prolongation ¢ 25
s over controls) 1.2 0.29 4.1 3.3 1.9 5.7
lyzed for HEV and HCV RNA. Twenty (40%) of these ¢25 seconds over controls. For all other variables, it
was the presence or absence of the event.had isolated HEV RNA, 7 (14%) had isolated HCV
RNA, and 11 (22%) had both HEV and HCV RNA. The
Multivariate Analysisremaining 12 (24%) patients did not have any viral
markers in their serum. Thus, HEV either in isolation Multiple stepwise logistic regression was performed
to discriminate survivors and nonsurvivors. The inde-or along with HCV was the causative agent in 31 (62%)
of these patients with FHF. None of these 50 patients pendent predictors of outcome were age ¢40 years,
grade of coma 2, presence of infection, serum biliru-had cryptic HBV infection.28
bin ¢15 mg/dL, and prolongation of prothrombin time
Prognostic Markers by ¢25 seconds over control (Tables 4 and 5). Cox’s
proportional hazard regression was then performed toThe clinical variables that influenced survival in our
patients are shown in Table 3. Older age, higher grades identify the independent predictors of outcome as well
as the duration of survival. This showed that four vari-of encephalopathy, smaller liver size on percussion,
presence of overt cerebral edema, and sepsis at admis- ables that independently predicted outcome were age
¢40 years, presence of cerebral edema at the time ofsion were detected in a significantly higher proportion
of patients who died in comparison with those who sur- hospitalization, serum bilirubin ¢15 mg/dL, and pro-
thrombin time ¢25 seconds over controls (Table 6).vived (P .01). The preencephalopathy period, icterus-
encephalopathy interval, and cause among the survi- To identify the predictive value of one or more of the
four variables on survival, five strata were constructed,vors and nonsurvivors were similar (Tables 1, 2). Other
hematologic and biochemical investigations were simi- depending on the number of adverse factors present. A
Kaplan-Meier analysis of each of these five groups islar among survivors and nonsurvivors.
shown Fig. 1. The pattern of survivors and nonsurvi-
Univariate Cox’s Analysis vors was significantly different in the five groups (P
 .01). The sensitivity and specificity of each groupUnivariate Cox’s regression was used to determine
if the outcome and the duration of survival were influ- depending on the number of adverse prognostic mark-
ers is shown in Table 7. It was seen that, with an in-enced by these variables. It was observed that all of
the variables found to be significantly associated with creasing number of adverse prognostic factors, the mor-
tality increased.outcome on simple analysis were also significant on the
univariate Cox’s regression.
DISCUSSION
Dichotomization of Predictive Factors The cause and clinical spectrum of FHF at our center
were different from those in the West.1,5 In the currentVariables found significant on Cox’s univariate re-
gression were then dichotomized for best discrimina- study, all patients had encephalopathy within 4 weeks
of onset of symptoms of hepatitis. These observationstion between survivors and nonsurvivors by the con-
struction of receiver-operated curves. The best cutoff are in contrast to reports from the United Kingdom,1,2
France,5 and Japan,3,4 where FHF has been docu-level for age was ¢40 years, grade of coma 2, liver
size ¡2 intercostal spaces on percussion, serum biliru- mented to occur up to 8 weeks after the onset of the
symptoms of acute hepatitis and jaundice. Four weeksbin ¢15 mg/dL, and prothrombin time prolongation of
TABLE 6. Cox’s Multiple Regression Analysis
Variable df Coefficient SE Coefficient/SE Global x2 P
1. Cerebral edema 1 0.87 0.14 5.95 58.8 .0001
2. Prothrombin time prolongation
¢ 25 s over controls 2 0.43 0.13 3.31 66.8 .0001
3. Serum bilirubin ¢ 15 mg/dL 3 0.29 0.13 2.18 73.2 .0001
4. Age ¢40 yr 4 0.29 0.14 2.02 77.2 .0001
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FHF, which was not substantiated in the current study.
Explanation for this difference is unclear. However,
mortality rates among pregnant patients compared
with nonpregnant females and males with FHF have
not been prospectively evaluated in any of the previous
studies.45-50
In the current study, one third of the patients had
evidence of either acute HBV or HAV or HDV infection,
and approximately 5% were diagnosed to have FHF
subsequent to use of antitubercular drugs (Table 2).
The remaining patients (n  264) had clinical features
suggestive of viral hepatitis, did not give history of con-
sumption of any identifiable hepatotoxins, and their
sera were negative for markers of acute HBV, HAV,
and HDV infection. We diagnosed them as patients
FIG. 1. Survival in patients with fulminant hepatic failure in with presumptive acute non-A, non-B viral infection,
relation to the presence of an increasing number of adverse prognos- although of course, alternative diagnosis, includingtic factors. The survival in the five strata were significantly different
toxic, drug-induced, or autoimmune hepatitis cannot(log rank test, P  .0001). Patients with three or four risk factors
did not differ significantly in the duration of survival (P  .08). be ruled out with certainty. Similar observations in-
criminating non-A, non-B virus as the major cause of
FHF have been reported from this country.52 Thus,
most of our patients with FHF and conceivably as manyafter onset of acute hepatitis, liver failure in this coun-
as 95% were caused by hepatotropic viral infection.try has a different clinical spectrum. It is recognized
HCV and HEV constitute the identifiable non-A, non-as subacute hepatic failure, a distinct clinical entity in
B viruses. Their role as causative agents of FHF inwhich liver failure appears as progressive ascites, and
sporadic setup has remained unclear.53-57 HEV couldencephalopathy is rare.40,41 Thus, the definition of FHF
not be incriminated as a cause of sporodic fulminantfor the Indian subcontinent should be the onset of he-
hepatitis in the West.53-55 The current study docu-patic encephalopathy within 4 weeks of occurrence of
mented that HEV caused FHF in the sporadic setup insymptoms of acute hepatitis. The difference in the tim-
this country, which was evident by detection of HEVing of clinical presentation of FHF in our patients com-
RNA either in isolation or along with HCV RNA in 31pared with those reported from the United Kingdom
(62%) of the 50 non-A, non-B fulminant hepatitis whomay be related to the differences in causative agents
were tested for HEV and HCV RNA. HEV being en-and the host factors.42
demic in India, it may be an important causative agentA quarter of our female patients with FHF were preg-
among patients with non-A, non-B fulminant hepatitis.nant, which is higher than the 3% pregnancy rate
The role of HCV in FHF has remained controversial.among the female population in this country.43,44 How-
A study from Japan reported the presence of anti-HCVever, pregnancy per se or the duration of the gestation
antibody or HCV RNA among most patients withdid not influence the mortality in the current study.
FHF,56 whereas studies from France,57 the UnitedDuring epidemics of HEV infection, pregnant women
States,53,54 and the United Kingdom55 have not beenhave been reported to have a high risk of developing
able to implicate HCV as an important cause of FHF.acute hepatitis as well as FHF compared with nonpreg-
The documentation of HCV RNA in isolation (n  7)nant females and males.45-51 Based on these studies, it
or along with HEV RNA (n  11) among 50 non-A,is believed that pregnant women with FHF have higher
mortality than nonpregnant females and males with non-B FHF tested for these viruses indicate that either
TABLE 7. Assessment of Prognostic Indicators in Patients With FHF
Positive Negative Diagnostic
Variable No. Death Sensitivity Specificity Prediction Prediction Accuracy
Age ¢40 yr 86 72 83.7 38.3 25.7 90.2 47.5
Cerebral edema at admission 240 196 81.7 54.1 70 69.2 69.7
Serum bilirubin (¢15 mg/dL) 182 141 77.5 46.8 56.6 69.9 61.3
Prothrombin time (¢25 s over control) 154 126 81.8 42.8 45 80.4 57.0
Multiple adverse factors present
Any 1 factor 146 82 56.1 79.7 86.3 44.3 63.3
Any 2 factors 115 93 80.9 79.7 87.7 69.9 80.4
Any 3 factors 86 80 93 79.7 86.0 89.5 87.3
All 4 factors* 13 12 92.3 79.7 48 98.1 81.8
* All four factors were present only in 13 patients. This resulted in an apparently lower prediction of mortality in these patients. This is
attributable to the small number of patients assessed in this group.
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HCV infection caused the disease or an HCV carrier institution, ‘‘overt cerebral edema’’ was diagnosed
based on clinical neurological findings (clinical diag-state made these patients more susceptible to another
hepatotropic viral infection, resulting in severe liver nostic criteria are mentioned previously in Patients
and Methods).24,62 We recognize that this probably un-injury. The latter possibility seems more probable be-
cause (1) most non-A, non-B FHF with HCV RNA in derestimates the true incidence of cerebral edema in
our population with FHF. Nevertheless, given thistheir sera also had HEV RNA (11 of 18, 61%); and
(2) Western reports could not incriminate HCV as an available parameter, our data suggest that ‘‘overt cere-
bral edema,’’ when recognizable clinically, carries withisolated cause of FHF.53,55,57
Thus, in contrast to Western studies, where drugs, it a very poor prognosis.
In conclusion, the current study is the largest re-hepatitis A, and hepatitis B viruses are the major
causes of FHF, non-A, non-B presumably was the major ported series on hepatotropic virus–induced FHF in a
tropical developing region. All of the patients with FHFcause of FHF in the current study.
Studies from the West have incriminated the cause in this series developed hepatic encephalopathy within
4 weeks of onset of acute hepatitis. Most of the FHFof FHF and rapidity of onset of encephalopathy after
occurrence of acute hepatic illness as important prog- were caused by presumptive non-A, non-B viral infec-
tion. HEV in the sporadic setup in its endemic regionnostic predictors.1-5 In these reports, FHF due to non-
A, non-B virus(es) and drugs had worse outcome than caused FHF. Mortality rate was highest within 72
hours of hospitalization. The prognostic model devel-other causes of FHF,1-3 and patients with the most
rapid onset of encephalopathy had the best chance of oped in this study was simple, reliable, rapid, and rele-
vant to patients in developing countries for assessmentrecovery.1,5 However in the current study, the causative
distribution and rapidity of onset of encephalopathy for liver transplantation.
was similar among survivors and nonsurvivors (Tables
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